The model that sees information flow linearly, from pharmaceutical companies, to healthcare professionals, or patient groups and patients, is outmoded and doesn’t work well for any of the parties involved.
Business development director at Star, Ryan Wooller, discusses commercial outsourcing and how the company has adapted to provide the best solutions as pharma companies look to innovate and reduce costs
Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.